Cargando…

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

BACKGROUND: Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune...

Descripción completa

Detalles Bibliográficos
Autores principales: Bastacky, Melissa L., Wang, Hong, Fortman, Dylan, Rahman, Zahra, Mascara, Gerard P., Brenner, Timothy, Najjar, Yana G., Luke, Jason J., Kirkwood, John M., Zarour, Hassane M., Davar, Diwakar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662734/
https://www.ncbi.nlm.nih.gov/pubmed/34900695
http://dx.doi.org/10.3389/fonc.2021.749064
_version_ 1784613501547839488
author Bastacky, Melissa L.
Wang, Hong
Fortman, Dylan
Rahman, Zahra
Mascara, Gerard P.
Brenner, Timothy
Najjar, Yana G.
Luke, Jason J.
Kirkwood, John M.
Zarour, Hassane M.
Davar, Diwakar
author_facet Bastacky, Melissa L.
Wang, Hong
Fortman, Dylan
Rahman, Zahra
Mascara, Gerard P.
Brenner, Timothy
Najjar, Yana G.
Luke, Jason J.
Kirkwood, John M.
Zarour, Hassane M.
Davar, Diwakar
author_sort Bastacky, Melissa L.
collection PubMed
description BACKGROUND: Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune activation. The link between irAE development and clinical outcome in melanoma and other cancers is inconsistent; and little data exists on the occurrence of multiple irAEs. We sought to characterize development of single and multiple irAEs, and association of irAE(s) development with clinical variables and impact upon outcomes in advanced melanoma patients treated with anti-PD-1 ICIs. METHODS: We conducted a retrospective study of 190 patients with metastatic melanoma treated with single-agent anti-PD-1 ICI therapy between June 2014 and August 2020 at a large integrated network cancer center identified through retrospective review of pharmacy records. irAEs were graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: 190 patients were evaluated of whom 114 patients (60.0%) experienced ≥1 irAE, including 30 (15.8%) with grade 3/4 irAEs. The occurrence of any irAE was strongly associated with the development of investigator-assessed response to anti-PD-1 therapy (p < 0.0001); whether evaluated by current (p=0.0082) or best (p=0.0001) response. In patients with ≥2 irAEs, distinct patterns were observed. Median progression-free survival (PFS) and overall survival (OS) were greater in those with any irAE compared to those without (PFS, 28 months vs. 5 months, p < 0.0001; OS, not reached vs. 9 months, p < 0.0001). Development of ≥2 irAEs had a trend towards improved PFS and OS compared to those who developed a single irAE, although this did not reach statistical significance (p=0.2555, PFS; p=0.0583, OS). Obesity but not age or gender was distinctly associated with irAE development. CONCLUSIONS: In this study, we demonstrated that irAE occurrence was significantly associated with response to anti-PD-1 therapy and improved PFS/OS. Those who developed multiple irAEs had a trend towards improved PFS and OS compared to those who developed only a single irAE. Increased BMI but neither age nor gender were associated with irAE development. Distinct patterns of irAEs observed suggest shared etiopathogenetic mechanisms.
format Online
Article
Text
id pubmed-8662734
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-86627342021-12-11 Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis Bastacky, Melissa L. Wang, Hong Fortman, Dylan Rahman, Zahra Mascara, Gerard P. Brenner, Timothy Najjar, Yana G. Luke, Jason J. Kirkwood, John M. Zarour, Hassane M. Davar, Diwakar Front Oncol Oncology BACKGROUND: Anti-PD-1 immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of melanoma by producing durable long-term responses in a subset of patients. ICI-treated patients develop unique toxicities - immune related adverse events (irAEs) – that arise from unrestrained immune activation. The link between irAE development and clinical outcome in melanoma and other cancers is inconsistent; and little data exists on the occurrence of multiple irAEs. We sought to characterize development of single and multiple irAEs, and association of irAE(s) development with clinical variables and impact upon outcomes in advanced melanoma patients treated with anti-PD-1 ICIs. METHODS: We conducted a retrospective study of 190 patients with metastatic melanoma treated with single-agent anti-PD-1 ICI therapy between June 2014 and August 2020 at a large integrated network cancer center identified through retrospective review of pharmacy records. irAEs were graded based on the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. RESULTS: 190 patients were evaluated of whom 114 patients (60.0%) experienced ≥1 irAE, including 30 (15.8%) with grade 3/4 irAEs. The occurrence of any irAE was strongly associated with the development of investigator-assessed response to anti-PD-1 therapy (p < 0.0001); whether evaluated by current (p=0.0082) or best (p=0.0001) response. In patients with ≥2 irAEs, distinct patterns were observed. Median progression-free survival (PFS) and overall survival (OS) were greater in those with any irAE compared to those without (PFS, 28 months vs. 5 months, p < 0.0001; OS, not reached vs. 9 months, p < 0.0001). Development of ≥2 irAEs had a trend towards improved PFS and OS compared to those who developed a single irAE, although this did not reach statistical significance (p=0.2555, PFS; p=0.0583, OS). Obesity but not age or gender was distinctly associated with irAE development. CONCLUSIONS: In this study, we demonstrated that irAE occurrence was significantly associated with response to anti-PD-1 therapy and improved PFS/OS. Those who developed multiple irAEs had a trend towards improved PFS and OS compared to those who developed only a single irAE. Increased BMI but neither age nor gender were associated with irAE development. Distinct patterns of irAEs observed suggest shared etiopathogenetic mechanisms. Frontiers Media S.A. 2021-11-26 /pmc/articles/PMC8662734/ /pubmed/34900695 http://dx.doi.org/10.3389/fonc.2021.749064 Text en Copyright © 2021 Bastacky, Wang, Fortman, Rahman, Mascara, Brenner, Najjar, Luke, Kirkwood, Zarour and Davar https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Bastacky, Melissa L.
Wang, Hong
Fortman, Dylan
Rahman, Zahra
Mascara, Gerard P.
Brenner, Timothy
Najjar, Yana G.
Luke, Jason J.
Kirkwood, John M.
Zarour, Hassane M.
Davar, Diwakar
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title_full Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title_fullStr Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title_full_unstemmed Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title_short Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis
title_sort immune-related adverse events in pd-1 treated melanoma and impact upon anti-tumor efficacy: a real world analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8662734/
https://www.ncbi.nlm.nih.gov/pubmed/34900695
http://dx.doi.org/10.3389/fonc.2021.749064
work_keys_str_mv AT bastackymelissal immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT wanghong immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT fortmandylan immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT rahmanzahra immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT mascaragerardp immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT brennertimothy immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT najjaryanag immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT lukejasonj immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT kirkwoodjohnm immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT zarourhassanem immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis
AT davardiwakar immunerelatedadverseeventsinpd1treatedmelanomaandimpactuponantitumorefficacyarealworldanalysis